iRS – from idea to innovation.
The betaSENSE technology detects changes in relevant proteins in the body long before the first symptoms of neurodegenerative diseases manifest. Thanks to iRS, the personal risk of disease can be determined precisely on the basis of a small sample of body fluids. This gives physicians and affected persons a valuable head start for therapies – and at the same time sets the course for the development of new drugs. Making independence in old age a matter of course in the future.
The betaSENSE teams – many areas of expertise, one shared goal.At betaSENSE, around 50 employees are currently working to combat neurodegenerative diseases such as Alzheimer’s, Parkinson’s or ALS at an early stage. Combining the power of various scientific disciplines for medical progress.
betaSENSE emerged from a group of researchers at the Ruhr University Bochum led by Prof. Dr. Klaus Gerwert. The most important milestones on the way since his appointment as professor in 1993 from basic research to international protein diagnostics pioneer: